TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›VTAK›Financials
Annual statements · SEC XBRL · FY2017 – FY2025

Catheter Precision, Inc. (VTAK) financials

Income statement

Catheter Precision, Inc. (VTAK) income statement, annual, from SEC filings
Fiscal yearFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$5.87M$6.26M$7.20M$259K$22.0K$14.0K$442K$420K$819K
Revenue growth—6.6%15.1%-96.4%-91.5%-36.4%3057.1%-5.0%95.0%
Gross profit$1.71M$2.05M-$1.65M-$1.91M-$1.54M-$147K$412K$378K$756K
Gross margin29.0%32.8%-22.9%-738.6%-6990.9%-1050.0%93.2%90.0%92.3%
Operating income-$17.8M-$31.2M-$57.7M-$35.4M-$29.3M-$27.0M-$78.1M-$11.2M-$21.1M
Operating margin-302.6%-498.0%-801.9%-13668.3%-133027.3%-192578.6%-17674.0%-2676.9%-2581.6%
Net income-$17.8M-$30.8M-$57.0M-$36.0M-$25.1M-$26.9M-$70.6M-$16.6M-$17.2M
Net margin-302.6%-492.8%-791.2%-13917.0%-113954.5%-191892.9%-15966.5%-3962.6%-2098.0%
EPS (diluted)-$2.35-$3.34-$108.28-$21.22-$248.22-$25.98———

Cash flow

Catheter Precision, Inc. (VTAK) cash flow, annual, from SEC filings
Fiscal yearFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$5.52M-$18.5M-$33.2M-$28.3M-$27.6M-$22.6M-$20.6M-$9.27M-$8.30M
Capital expenditures$547K$582K$268K$67.0K$265K$17.0K$76.0K$67.0K$17.0K
Free cash flow-$6.07M-$19.1M-$33.4M-$28.4M-$27.9M-$22.6M-$20.7M-$9.34M-$8.31M

Balance sheet

Catheter Precision, Inc. (VTAK) balance sheet, annual, from SEC filings
Fiscal yearFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$8.24M$64.3M$14.6M$23.9M$15.0M$15.9M$3.56M$2.87M$88.0K
Total assets$11.3M$74.0M$44.1M$33.4M$21.0M$16.8M$30.7M$27.8M$15.9M
Total liabilities$18.9M$7.33M$10.9M$12.3M$7.37M$7.58M$9.54M$16.0M$9.21M
Long-term debt—$850K$558K—————$3.08M
Shareholders' equity-$7.62M$66.7M$33.1M$21.1M$13.7M$9.26M$21.2M$11.8M$7.05M
Retained earnings-$29.4M-$60.2M-$117M-$153M-$178M-$205M-$276M-$292M-$310M
Shares (wtd avg diluted)7.89M12.7M551K3.19B101K1.03M550K172K1.08M

Every figure is extracted from Catheter Precision, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is Catheter Precision, Inc.'s annual revenue?
Catheter Precision, Inc. (VTAK) reported $819K of revenue for fiscal year 2025 — up 95.0% from $420K in FY2024, per its annual report filed with the SEC.
Is Catheter Precision, Inc. profitable?
Not in FY2025 — VTAK reported a net loss of $17.2M, per SEC filings.
What is Catheter Precision, Inc.'s free cash flow?
-$8.31M in FY2025 (operating cash flow -$8.30M minus $17.0K of capital expenditures), from the SEC cash-flow statement.
Does VTAK pay a dividend?
Catheter Precision, Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full VTAK analysis — verdict, score & filings →Is VTAK a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.